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mortality depends on epidemiological evidence relating reduced risk to HAQ improve-
ment.. Costs and utilities associated with different HAQ levels were based on data 
from cohort studies and cross-sectional surveys in Italy. RESULTS: In the base case    
scenario (10% of patients treated in each disease state) we estimated that treatment 
with any biologic had an incremental cost of 26.4% over 10 years (including only            
direct costs). By analysing each disease state separately, costs vary from 22.3% to            
28.3%. The inclusion of potential avoided nursing home admissions and indirect          
costs/lost employment further improved the cost-effectiveness ratio. The model shows 
that a higher percentage of treated patients with a HAQ score between 1.1 and 2.6 
improves the cost-effectiveness ratio. The greater effectiveness of biological agents      
contribute to maintaine patients in less severe disease states by favoring disease 
improvement and remission; this signiﬁcant health beneﬁt is also reﬂected on mortality 
rate. Sensitivity analyses showed long-term HAQ progression with biologic therapies         
and discounting as most sensitive variables. CONCLUSIONS: Our results suggest that    
biologic therapies are cost-effective when compared with DMARDs. The model is 
further suitable for use in a wide range of other cost-effectiveness questions in rheu-
matoid arthritis. It appears to accurately capture disease progression and its effects 
and can therefore be useful for estimating cost-effectiveness of new treatments in RA 
in different Italian health care settings.
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OBJECTIVES: To evaluate the annual economic impact of biotherapies for the treat-
ment of RA patients. METHODS: Target population was deﬁned as adults belonging 
to RA medical Diagnosis Related Group (DRG) in the French national database of 
the Information System Program Management (PMSI) in hospital. The total direct 
costs considered were: treatment costs (current published prices, April 2009), hospi-
talization costs including administration cost in hospital (DRG, V11 March 2009), 
and for ambulatory patients the rheumatologist follow-up and subcutaneous injection 
costs. Treatment cost was calculated according to treatment dose, length and duration 
as reported in real life data. Real life data were based on a registry (AIR PR) and 
record from market analysis (A  A panel study March 2008). Biotherapies market 
share data were issued from the GFK Performance Tracker (Q3 2008). RESULTS: A 
total of 15,873 patients were identiﬁed in 2007 with biotherapies of Abatacept: 952 
(6), a19,618 (81), a18,676,336 (8); Adalimumab: 4762 (30),   a14,950 (patient injec-
tion) (99), a15,464 (nurse injection) (98), a71,252,500 (32); Etanercept: 5873 (37),   
a14,693 (patient injection) (99), a14,849 (nurse injection) (98), a86,575,567 (39); 
Inﬂiximab*: 2381 (15), a 12,144 (84), a28,914,864 (13); Rituximab**: 1905 (12),   
a 6,451 1 cycle (89) a12,789 2 cycles (90), a16,029,434 (7); Total: 15873 (100), NA,   
a221,448,701 (100) for Patients N (%), Annual costs / patient (% acquisition costs),          
Total annual costs (%).CONCLUSIONS: In real life setting annual RA treatment 
costs/patient in France varies from a6,451 to a19,618 depending on the biotherapy 
used. Drug acquisition cost represents the major part of the annual costs. The global 
annual cost is a221, 448, 701.
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BACKGROUND: Rheumatoid arthritis (RA) is a systemic autoimmune disease which 
affects about 0.5% of the population in developing countries. The current biologic 
DMARDs approved in Brazil as 1st line therapy are: inﬂiximab, etanercept, adalim-
umab (anti-TNF therapies), abatacept (T-cell co-stimulation therapy) or tocilizumab 
(IL-6 receptor antagonist). OBJECTIVES: To assess the budget impact of offering 
tocilizumab as an option to a pool of patients with rheumatoid arthritis (RA) in Brazil. 
METHODS: The perspective is private payer in Brazil. Only direct costs were consid-
ered which comprised of: drug, management and administrations costs [Scheinberg et 
al. 2005]. Drug costs were taken from public sources [Kairos magazine. May, 2009]. 
Base case dosages considered were: tocilizumab (8 mg/kg dosage each 4 weeks) and 
inﬂiximab {4.3 mg/kg (Ollendorf et al. 2005) at weeks 0, 2, 6 and every 8 weeks}, 
assuming a 70 kg patient, adalimumab (40 mg every other week), etanercept (50 mg 
every week) and abatacept (750 mg at weeks 0, 2, 4 and then every 4 weeks). The 
discount rate taken was 5% according to the Brazilian guidelines for Health Technol-
ogy Assessment (HTA) [Vianna et al. 2007] since a 5-year horizon was taken for this 
analysis. Both the treatment mix forecast and the tocilizumab penetration change were 
projected based on market research data. The results are expressed in 2009 Brazilian 
Reais (US$1 y $Brz2.5). RESULTS: Total annual costs were $Brz81,021 for tocili-
zumab, $Brz92,789 for etanercept, $Brz98,541 for adalimumab, $Brz105,283 for 
inﬂiximab and $Brz 85,020 for abatacept. Based on the change in the forecast;, a total 
savings for a period of 5 years were $Brz1,573,902 for each 100 treated patients, 
when comparing the group of patients received tocilizumab to the group of patients 
that did not receive tocilizumab. CONCLUSIONS: Findings suggest tocilizumab offers 
potential costs reductions in the private health care system in Brazil.
PMS17
BUDGET IMPACT ANALYSIS OF REIMBURSEMENT OF ARAVA® 
(LEFLUNOMIDE) IN THE TREATMENT OF RHEUMATOID ARTHRITIS  
IN POLAND
Kawalec P1, Gierczynski J2, Lis J2, Glasek M2
1Centrum HTA, Krakow, Poland, 2Sanoﬁ-Aventis, Warsaw, Poland
OBJECTIVES: The aim of the analysis was to assess the impact on the Polish health 
care budget the ﬁnancing of Arava® within ambulatory reimbursement list compared 
to Arava® ﬁnancing within the National Health Fund rheumatoid arthritis therapeutic 
program; all costs were calculated from public payer’s perspective in Poland in a one-
year time horizon. METHODS: Direct medical costs regarding drug costs, diagnostic 
costs, ambulatory and hospital treatment valid from a public payer’s perspective were 
taken into account in the analysis. Ofﬁcial retail price of Arava® was obtained from 
Sanoﬁ-Aventis from Poland. Five reimbursement scenarios were taken into consider-
ation depending on reimbursement limits and levels of coverage by public payer. 
RESULTS: Introduction of Arava® on ambulatory reimbursement list results in incre-
mental savings between 4.4 million PLN and 6.4 million PLN (depending on reim-
bursement scenario) comparing to continuation of Arava® treatment within the 
rheumatoid arthritis therapeutic program from public payer’s perspective. Financing 
Arava® within reimbursement list could increase number of patients treated with a 
Arava® from around 4.3 thousands to 5,3 thousands (at present 3 thousands of 
patients are treated with leﬂunomide within therapeutic program) or extend duration 
of treatment with additional from 5 up to 9 months. CONCLUSIONS: Financing 
Arava® within ambulatory reimbursement list generates substantial savings for the 
public payer in Poland compared to ﬁnancing within a therapeutic program and pro-
vides treatment with Arava® for a greater number of patients with rheumatoid arthritis 
or extends the duration of treatment.
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OBJECTIVES: To describe the disease management and the cost of patients presenting 
a diagnosis of sciatica in the hospital perspective. METHODS: We performed a local 
data base request from the medical information system (PMSI) of the University Hos-
pital of Montpellier. We considered three consecutive years (2006, 2007, 2008) which 
allowed us to get a follow-up and a traceability of patients over this period. We ana-
lyzed a group of patients 18–50 years old admitted across acute care, day care or 
mid-term care sectors with the following diagnosis codes M 54, M 5415, M 5416 and 
M 5417 of the ICD-10. RESULTS: A total of 232 patients were selected over the 
period representing a total of 541 admissions (i.e. 2.3 admissions per patient). The 
mean o SD age was 39 o 8 years female represent 45% of the patients. We observed 
175 admissions in acute care (“less than 24 h” admissions excluded) with a mean 
length of stay of 7 o 5.2 days. Day-care represents 15.4% of admission in acute care 
sector. We observed 38 admissions in mid-term care with a mean length of stay of 3 
o 4.8 days. Few patients (3 %) were admitted consecutively in acute care and in mid 
term care thereafter. Surgery was the reason of ﬁrst admission for six patients. The 
cost is estimated at a2055 per patient admitted in an acute care sector. CONCLU-
SIONS: In our sample, we noted a high rate of admission per patient for diagnosis, 
medical treatment or physical therapy reasons as the main pattern of sciatica manage-
ment in-hospital. Admissions for surgery were marginal. Our ﬁgures are key informa-
tion to specify management of sciatica and transition probabilities in decision tree 
models. Thus, we would simulate the impact of innovative medical device on the 
burden of disease and disclose where are the most prominent societal beneﬁts.
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BACKGROUND: Rheumatoid arthritis (RA) is a systemic autoimmune disease which 
affects 0.5% of the population in developing countries. The current biologic DMARDs 
approved in Brazil as 1st line therapy are: inﬂiximab, adalimumab, etanercept, (anti-
TNF therapies) and abatacept (T-cell co-stimulation therapy) or tocilizumab (IL-6 
receptor antagonist). OBJECTIVES: To assess the budget impact of offering tocili-
zumab as an option to a pool of patients with RA in Brazil. METHODS: The perspec-
tive was from a public payer. Only direct costs were considered which comprised: 
drug, management and administrations costs [Scheinberg et al. 2005]. Base case 
dosages considered were: tocilizumab (8 mg/kg dosage each 4 weeks) and inﬂiximab 
[4.3 mg/kg (Ollendorf et al. 2005) at weeks 0, 2, 6 and every 8 weeks], assuming a 
70 kg patient, adalimumab (40 mg every other week), etanercept (50 mg every week) 
and abatacept (750 mg at weeks 0, 2, 4 and then every 4 weeks). We took the 
maximum price to government as a basis to all therapies [Jun, 2009]. The discount 
rate taken was 5% according to the Brazilian guidelines for (HTA) [Vianna et al. 
2007] and a 5-year horizon was assumed. Both the treatment mix forecast and the 
tocilizumab penetration change were projected based on market research data. The 
results are expressed in 2009 Brazilian Reais (US$ 1 y $Brz2.5). RESULTS: Total 
annual costs were $Brz47,566 for tocilizumab, $Brz50,785 for etanercept, $Brz53,909 
for adalimumab, $Brz58.603 for inﬂiximab and $Brz50,048 for abatacept. Based on 
the change in the mix of treatment forecast, a total savings for a period of 5 years 
